Google
GOSS — GOSSAMER BIO INC (Healthcare >> Biotechnology)
GOSS FAQ
What is GOSS's ROE?
GOSSAMER BIO INC reports a Return on Equity (ROE) of 111.71%.
What is GOSS's dividend yield?
GOSSAMER BIO INC offers a dividend yield of 0.00%.
What is GOSS's Deepscope Quality Score?
Deepscope rates GOSS's overall financial quality at 23 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy GOSS?
Deepscope's AI Timing Score for GOSS is 28 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does GOSS belong to?
GOSSAMER BIO INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 0.19
Price
-0.01
(-5.94%)
Day Change
|
|
|---|
GOSS, the overall quality is not good ( Quality = 23) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
ROE is decreasing significantly
ROA is too relatively low compare to ROE
Growth of ROA was below our criteria in the last year.
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...
| Quality Factors |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 78 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 0.19 |
| PBV / Sector |
-0.29 / 4.48
|
| Earning Per Share | -0.72 |
| PE / Sector |
N/A / 16.68
|
| PEG or PE/Growth / Sector |
N/A / 0.53
|
| Average 1M Daily Value |
2.97 M
GREAT
|
| Average 1W Daily Value |
2.79 M
GREAT
|
| Timing Factors |
|
42% |
| Financial Health |
|
41% |
| Ability to Make Profit |
|
52% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-04 09:24:12 |
| Symbol | GOSS |
| Name | GOSSAMER BIO INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 234.70 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 46.99 / 8,483.11 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 3115 Merryfield Row, San Diego, CA, United States, 92121
Phone: 858 684 1300
Website: https://www.gossamerbio.com
Employees: 161
Sector: Healthcare >> Biotechnology
Description: Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
